🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524456-58-00
Authorised Phase I/II

A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults

2025-524456-58-00 · tracked via the Priya Life Science EU tracker
Sponsor
GlaxoSmithKline Biologicals
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
04/06/2026
Enrollment target
464
Sites
Belgium

Condition studied

Respiratory Syncytial Virus Infections+Metapneumovirus

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524456-58-00 on CTIS ↗ ← All trials in the EU